Contact Us

MedCity INVEST Precision Medicine spotlight: Building a BioInnovation Hub

Sponsored by Independence Blue Cross, the panel, What It Takes To Build A Successful, Regional BioInnovation Hub, focuses on Philadelphia — one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries. What do cities need to do to address education, training and other needs to support these sectors? This session was held as part of Venture Café Philadelphia .

Read full story

December 30, 2020

Philadelphia – A Biopharma Hub on the Move

Philadelphia is not just the city of brotherly love. It is one of the nation’s top biopharma hubs and the birthplace of cell and gene therapy. Within the next few years, the role of life sciences companies and institutions that call the city home is expected to grow at an accelerated rate, further cementing the city’s place as a key biopharma ecosystem.

When the dust of the ongoing COVID-19 pandemic settles, key industry leaders see a significant opportunity for Philadelphia to become a next-generation biopharma hub. During the Dec. 10 MedCity INVEST Precision Medicine conference, Audrey Greenberg, Executive Managing Director of The Discovery Labs, said many of the keys are already in place for Philadelphia to become a top-five biopharma hub, including innovative science in the cell and gene therapy space, top hospitals and strong education and training programs…

Read full story

December 14, 2020

Pandemic Did Not Slow Center of Breakthrough Medicines in King of Prussia’s Discovery Labs

Despite the pandemic, development of the Center for Breakthrough Medicines in King of Prussia’s Discovery Labs innovation hub is still on track to be finalized and occupied by the end of next year, writes Queen Muse for the Philadelphia Magazine.

Developer Brian O’Neill and biotech executive Audrey Greenberg have joined forces with health-care investment firm Deerfield Management from New York City to develop the 630,000-square-foot cell and gene therapy manufacturing facility.

The site broke ground in December 2019. When it is completed, the property will offer contract development and manufacturing organization space and research and development labs, as well as administrative offices and dining, daycare, and fitness amenities…

Read full story

December 10, 2020

How Philly’s Bioscience Sector Is Driving the City’s Next Big Real Estate Boom

Philadelphia’s life sciences sector is right about where Michael Jordan was in 1989.

If you’re into sports history, you know 1989 was a break-out year for Jordan, one in which he’d score the first of many history-making, game-winning shots. And even though it would be two years before he’d win his first league championship — and another two years before he’d carry his team to its first three-peat, earning its dynasty title in the process — if you hadn’t noticed Jordan before then, that was the year you started to pay attention. For Philly, 2017 was the year the city’s life sciences sector clinched “the shot.” The city celebrated two first-of-their-kind FDA-approved gene and cell therapies to treat specific types of cancer and blindness. And by the end of 2019, things were looking more promising than ever…

Read full story

December 8, 2020

Can Cell and Gene Therapies Achieve Their Full Potential?

CBM has Cell Therapy Manufacturing capabilities in Philadelphia

Cell and gene therapies (C&GTs) have made huge advances in a few short decades. By February 2020, five therapies were on the market and FDA had approved nine more, while 362 treatments were in the US pipeline, up 25% from the previous year, according to the Pharmaceutical Research and Manufacturers of America’s latest survey (1). In September 2020, the first patient was dosed with autologous chimeric antigen receptor (CAR-T) lymphoma treatment using an automated closed system. “Despite complex and mainly manual processes, we can produce these therapies. Now we must work on making processes reproducible,” says Joerg Ahlgrimm, president and chief operating officer at The Discovery Labs, who was previously head of global C&GT operations at Lonza Pharma & Biotech. Significant progress has already been made, he notes. “The fact that we can routinely upscale a viral vector to 200–500 L standard represents a huge accomplishment. Years ago, we could not even have imagined reaching this point. And now, we are approaching 2000-L batch sizes,” he adds…

Read full story

December 4, 2020